Strategic Review of Cynata Clinical Development Portfolio
Filed with ASX · · 2 pages · English
Cynata Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Cynata Therapeutics
- Cynata announces CEO succession and Board changes
- Cynata Completes Oversubscribed Share Purchase Plan
- Share Purchase Plan Booklet & Option Prospectus
- Ethics Committee Approval for Proposed aGvHD Phase 2 Trial
- Capital Raising Presentation
Later from Cynata Therapeutics
- Phase 2 Trial of CYP-001 in aGvHD Open for Recruitment
- Approval of Clinical Trial of CYP-001 in Kidney Transplant
- Cynata Receives $2.315m R&D Tax Incentive Refund
- Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey
- Recruitment Completed in Phase 3 OA Clinical Trial
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics